The Autologous matrix-induced Chondrogenesis Market Is Estimated To Increase At A CAGR Of 8.6 Percent During The Forecast Period
AMIC stands for Autologous matrix-induced Chondrogenesis, and it is a biological treatment for articular cartilage injury. AMIC treatment is a multi-step procedure. First, following microfracture surgery, a bi-layer collagen I/III membrane is applied. Second, it reduces cartilage deterioration in the hopes of avoiding or postponing partial or total minor joint replacement surgery (e.g., knee replacement). In terms of value, the global Autologous matrix-induced Chondrogenesis Market is expected to grow at a CAGR of 8.6% over the forecast period. The need for minimally invasive operations has risen dramatically in recent years. Patients choose minimally invasive operations because of benefits such as fewer post-surgery problems and side effects, a quicker patient recovery time, and a shorter hospital stay. As a result, the autologous matrix-induced chondrocyte is likely to grow in popularity as the demand for minimally invasive operations rises. Autologous matrix-induced chondrogenesis